Centogene N.V. (CNTG) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Centogene N.V. (CNTG) Healthcare & Pipeline Overview

Centogene N.V. focuses on rare diseases, leveraging a data and biological repository to enhance the identification and monitoring of hereditary diseases. The company provides diagnostic services, COVID-19 testing, and collaborates with pharmaceutical companies to accelerate orphan drug development, operating primarily in the global healthcare market.

What Is the Investment Thesis for CNTG?

Centogene N.V. presents a unique investment opportunity within the rare disease diagnostics and pharmaceutical support sector. The company's rare disease platform and extensive data repository provide a competitive advantage in identifying and monitoring rare hereditary diseases. Key value drivers include the expansion of pharmaceutical collaborations and the growth of diagnostic services. The company's gross margin stands at 35.5%. Upcoming catalysts include potential new partnerships with pharmaceutical companies and the expansion of diagnostic testing services into new geographic markets. However, the company's negative profit margin of -73.2% and reliance on collaborations pose significant risks. Investors should closely monitor the company's ability to achieve profitability and sustain revenue growth through its core business segments.

Based on FMP financials and quantitative analysis

CNTG Key Highlights

• Centogene's focus on rare diseases positions it in a high-growth area of the healthcare market.
• The company's rare disease platform and data repository offer a competitive advantage in identifying and monitoring hereditary diseases.
• Gross margin of 35.5% indicates potential for profitability with increased operational efficiency.
• Collaboration agreements with major pharmaceutical companies like Pfizer and Takeda provide revenue streams and validation of Centogene's platform.
• The company's COVID-19 testing services provided a temporary revenue boost, but the long-term focus remains on rare disease diagnostics and pharmaceutical support.

Who Are CNTG's Competitors?

CNTG is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are CNTG's Key Strengths?

• Specialized focus on rare diseases.
• Proprietary rare disease platform and data repository.
• Collaboration agreements with major pharmaceutical companies.
• Expertise in genetic sequencing and diagnostics.

What Are CNTG's Weaknesses?

• Negative profit margin.
• Reliance on pharmaceutical collaborations for revenue.
• Limited geographic presence.
• Dependence on COVID-19 testing revenue.

What Could Drive CNTG Stock Higher?

• Potential new partnerships with pharmaceutical companies to leverage Centogene's rare disease platform for drug development.
• Expansion of diagnostic testing services into new geographic markets to increase revenue streams.
• Continued development of new diagnostic tests for rare diseases to expand service offerings.
• Leveraging real-world data for personalized medicine solutions for patients with rare diseases.
• Strategic acquisitions and partnerships to expand capabilities and market reach in the rare disease diagnostics and therapeutics space.

What Are the Key Risks for CNTG?

• Financial-distress signal — its Altman Z-Score of -4.03 sits in the distress zone (elevated bankruptcy risk).
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Competition from larger diagnostic companies with broader service offerings.
• Changes in the regulatory landscape for genetic testing impacting Centogene's business model.
• Decline in COVID-19 testing revenue affecting overall financial performance.
• Economic downturn impacting healthcare spending and demand for diagnostic services.
• Dependence on pharmaceutical collaborations for revenue, which may be subject to termination or renegotiation.

What Are the Growth Opportunities for CNTG?

• Expansion of Pharmaceutical Collaborations: Centogene has the opportunity to expand its collaborations with pharmaceutical companies to leverage its rare disease platform for drug development and clinical trials. The market for orphan drugs is projected to reach $262 billion by 2026, presenting a significant revenue opportunity for Centogene through partnerships and licensing agreements. Timeline: Ongoing.
• Geographic Expansion of Diagnostic Services: Centogene can expand its diagnostic testing services into new geographic markets, particularly in regions with unmet needs for rare disease diagnosis. The global diagnostics market is expected to grow to $125 billion by 2028, driven by increasing demand for genetic testing and personalized medicine. Timeline: 2-3 years.
• Development of New Diagnostic Tests: Centogene can invest in the development of new diagnostic tests for rare diseases to expand its service offerings and attract new customers. The market for genetic testing is projected to grow to $25 billion by 2027, driven by advancements in sequencing technologies and increasing awareness of genetic disorders. Timeline: 3-5 years.
• Leveraging Real-World Data for Personalized Medicine: Centogene can leverage its rare disease platform and real-world data to develop personalized medicine solutions for patients with rare diseases. The market for personalized medicine is expected to grow to $2.4 trillion by 2028, driven by advancements in genomics and data analytics. Timeline: 5+ years.
• Strategic Acquisitions and Partnerships: Centogene can pursue strategic acquisitions and partnerships to expand its capabilities and market reach in the rare disease diagnostics and therapeutics space. The healthcare industry is experiencing consolidation, with companies seeking to acquire innovative technologies and expand their service offerings. Timeline: Ongoing.

What Opportunities Does CNTG Have?

• Expansion of pharmaceutical collaborations.
• Geographic expansion of diagnostic services.
• Development of new diagnostic tests for rare diseases.
• Leveraging real-world data for personalized medicine.

What Threats Does CNTG Face?

• Competition from larger diagnostic companies.
• Changes in regulatory landscape for genetic testing.
• Decline in COVID-19 testing revenue.
• Economic downturn impacting healthcare spending.

What Are CNTG's Competitive Advantages?

• Proprietary Rare Disease Platform: Centogene's rare disease platform and data repository provide a competitive advantage in identifying and monitoring hereditary diseases.
• Extensive Data Repository: The company's data and biological repository includes epidemiologic, phenotypic, and heterogenetic data.
• Pharmaceutical Collaborations: Collaboration agreements with major pharmaceutical companies provide revenue streams and validation of Centogene's platform.
• Expertise in Rare Disease Diagnostics: Centogene has established expertise in rare disease diagnostics and genetic sequencing.

What Does CNTG Do?

Founded in 2006 and headquartered in Rostock, Germany, Centogene N.V. operates at the intersection of diagnostics and pharmaceuticals, focusing on rare diseases. The company's core mission is to transform real-world clinical and genetic data into actionable insights for patients, physicians, and pharmaceutical companies. Centogene operates through three primary segments: Pharmaceutical, Diagnostics, and COVID-19 testing. Its rare disease platform is a comprehensive data and biological repository that includes epidemiologic, phenotypic, and heterogenetic data. This platform enhances the identification and monitoring of rare hereditary diseases and facilitates the development of orphan drugs. Centogene provides a range of services, including target discovery, early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring. The company also offers genetic sequencing and diagnostics services directly to physicians, laboratories, and hospitals, as well as through distributors. In addition, Centogene provides COVID-19 testing solutions, including PCR and antigen testing services. The company has established collaboration and license agreements with several key players in the pharmaceutical industry, including Shire International GmbH, Pfizer Inc., Dr. Bauer Laboratoriums GmbH, Fraport AG, Takeda Pharmaceutical Company Limited, and Twist Bioscience Corporation. Centogene's integrated approach aims to accelerate the development and delivery of treatments for rare diseases, addressing a significant unmet need in the healthcare sector.

What Products and Services Does CNTG Offer?

• Focuses on rare diseases by transforming clinical and genetic data into actionable information.
• Operates a rare disease platform, a data and biological repository.
• Provides genetic sequencing and diagnostics services to physicians, laboratories, and hospitals.
• Offers target discovery, early patient recruitment, and biomarker discovery services.
• Provides epidemiological insights and patient monitoring.
• Develops solutions that accelerate the development of orphan drugs.
• Offers COVID-19 testing solutions, including PCR and antigen testing services.

How Does CNTG Make Money?

• Generates revenue through diagnostic testing services for rare diseases.
• Earns revenue from pharmaceutical companies through collaboration and licensing agreements.
• Provides COVID-19 testing services for revenue.
• Utilizes a data-driven approach to enhance the identification and monitoring of rare hereditary diseases.

What Industry Does CNTG Operate In?

Centogene N.V. operates within the medical diagnostics and research industry, which is experiencing growth driven by advancements in genetic sequencing and personalized medicine. The market for rare disease diagnostics and therapeutics is expanding, fueled by increased awareness and regulatory support for orphan drug development. Centogene's competitive landscape includes companies like Quest Diagnostics and Laboratory Corporation of America, which offer a broader range of diagnostic services, as well as specialized rare disease companies. Centogene differentiates itself through its comprehensive rare disease platform and focus on pharmaceutical collaborations.

Who Are CNTG's Key Customers?

• Physicians and hospitals seeking diagnostic services for patients with suspected rare diseases.
• Pharmaceutical companies developing orphan drugs for rare diseases.
• Laboratories requiring genetic sequencing and diagnostic services.
• Individuals seeking COVID-19 testing services.

How Centogene N.V. Is Valued

Centogene N.V. carries a market capitalization of $9.42M, placing it in the micro-cap category. Relative to its peer group, CNTG's quantitative score of 50/100 is below the peer average of 62/100.

ROE 398%Key Financial Metrics

Return on equity for Centogene N.V. stands at 397.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -46.1%, showing how much profit it generates from its asset base. A current ratio of 1.02 indicates the company holds enough short-term assets to cover its near-term obligations.

F-Score 2/9Financial Health

Centogene N.V.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -4.03 places it in the distress zone, a signal of elevated financial risk.

CNTG Financials

CNTG Latest News

No recent news available for CNTG.

CNTG Analyst Consensus

CNTG MoonshotScore

Common Questions About CNTG (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources